OpenAlex
PricingAboutJobs
Log inGet started
Work

Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management.

PubMed

Year: 2014
Type: article
Source: PubMed
Authors: Hao Xiong, Rajendra S Pradhan, Adel Nada, Andrew P Krivoshik, Kyle D Holen, James W Rhodes, Gary B Gordon, Rod Humerickhouse, Walid M Awni
Institutions: AbbVie (United States), Alexion Pharmaceuticals (United States), Neostem (United States), Astellas Pharma (United States)
Language: English

Topic: Statistical Methods in Clinical Trials
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Keywords: navitoclax, BCL-2 inhibitor, anticancer agents, risk-benefit assessment, risk management plan, relative bioavailability, food effect, dose selection, formulation selection, drug tolerability
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2343717137
FWCI: 1.27
Cites: 2
Cited by: 22
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security